Company news

Geron Corporation news in 2023

Geron Corporation's news releases, calls and decks from 2023, newest first.

View company

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

December 10, 2023

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

December 5, 2023

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

December 3, 2023

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

November 27, 2023

Geron to Participate at Upcoming Investor Conferences in November

November 6, 2023

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

November 1, 2023

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results

November 1, 2023

Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023

October 25, 2023

Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

September 28, 2023

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer

September 10, 2023

Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting

September 6, 2023

Geron to Participate in the Baird 2023 Global Healthcare Conference

September 4, 2023

Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

August 21, 2023

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS

August 20, 2023

Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

August 2, 2023

Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023

July 26, 2023

Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

June 28, 2023

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 21, 2023

Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat

June 19, 2023

Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

June 12, 2023

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

June 11, 2023

Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Geron to Host Virtual Investor Event on June 14, 2023

June 5, 2023

Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients

June 1, 2023

Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

May 24, 2023

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

May 10, 2023

Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights

May 10, 2023

Geron to Announce First Quarter 2023 Financial Results on May 11, 2023

May 3, 2023

Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial

April 25, 2023

Geron to Present at Upcoming Investor Conferences in April

April 11, 2023

Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones

March 15, 2023

Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023

March 8, 2023

Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference

January 11, 2023

Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.

January 10, 2023

Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million

January 9, 2023

Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

January 4, 2023

Geron Corporation Announces Proposed Public Offering of Common Stock

January 3, 2023

Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

January 3, 2023

Geron Announces Conference Call for Top-Line Results from IMerge Phase 3

January 2, 2023

Calls in 2023

Decks in 2023